About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

100.55 -0.75 (-0.75%)

Streaming Delayed Price Updated: 10:33 AM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

This Healthcare Stock is Down By More Than 50%: Here's 25 Stocks Moving Premarket ↗

July 13, 2022

Gainers

Via Benzinga

Boeing, PriceSmart And 80 Biggest Movers From Yesterday ↗

July 13, 2022

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.

Via Benzinga

Rhythm Pharma's Setmelanotide Shows Encouraging Action In Hypothalamic Obesity Study ↗

July 12, 2022

Via Benzinga

Crude Oil Prices Fall Sharply; Greenwich LifeSciences Shares Spike Higher ↗

July 12, 2022

U.S. stocks traded mixed toward the end of trading after recording losses in the previous session.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 12, 2022

Via Benzinga

Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session ↗

July 12, 2022

Gainers

Via Benzinga

5 Analysts Have This to Say About Rhythm Pharmaceuticals ↗

June 17, 2022

Rhythm Pharmaceuticals (NASDAQ:RYTM) has observed the following analyst ratings within the last quarter:

Via Benzinga

Rhythm Pharma Secures Non-Dilutive Financing Of $100M To Use Of This... ↗

June 17, 2022

Via Benzinga

Expert Ratings for Rhythm Pharmaceuticals ↗

May 24, 2022

Analysts have provided the following ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) within the last quarter:

Via Benzinga

Rhythm Shares Climb Following Positive Interim Results From Mid-Stage Obesity Study ↗

July 12, 2022

Rhythm Pharmaceuticals (NASDAQ: RYTM) announced positive interim results from a Phase 2 clinical trial evaluating setmelanotide for the treatment of severe obesity and hyperphagia in people living with...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 07, 2022

Gainers

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗

July 01, 2022

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Via Benzinga

33 Stocks Moving In Friday's Mid-Day Session ↗

June 17, 2022

Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy.

Via Benzinga

The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease ↗

June 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

U.S. Markets Open Higher; Dow Rises Around 200 Points ↗

June 17, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Friday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

June 17, 2022

Good morning! We're entering the final day of trading for the week with a look at the biggest pre-market stock movers for Friday!

Via InvestorPlace

21 Stocks Moving in Friday's Pre-Market Session ↗

June 17, 2022

Gainers Athersys, Inc. (NASDAQ: ATHX) rose 48.5% to $0.4755 in pre-market trading after dropping more than 12% on Thursday.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

June 16, 2022

Gainers Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 34.4% to $2.81 during Thursday's after-market session. The market value of their outstanding shares is at $29.0 million.

Via Benzinga

Rhythm Pharmaceuticals' Shares Dive Following FDA's Verdict On IMCIVREE Drug ↗

June 16, 2022

The U.S. Food and Drug Administration (FDA) has approved Rhythm Pharmaceuticals’ (NASDAQ: RYTM) supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R)...

Via Benzinga

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗

June 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

27 Stocks Moving in Thursday's Pre-Market Session ↗

June 16, 2022

Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

June 14, 2022

Gainers

Via Benzinga

93 Biggest Movers From Yesterday ↗

June 14, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...

Via Benzinga

70 Stocks Moving In Monday's Mid-Day Session ↗

June 13, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric...

Via Benzinga

5 Biotech Stocks To Watch During The Week Of June 13 ↗

June 13, 2022

Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a...

Via Benzinga

30 Stocks Moving in Monday's Pre-Market Session ↗

June 13, 2022

Gainers G Medical Innovations Holdings Ltd (NASDAQ: GMVD) rose 53.6% to $0.5301 in pre-market trading after dropping more than 28% on Friday.

Via Benzinga

6 Biotech Stocks to Buy Now Ahead of These June Catalysts ↗

June 03, 2022

These biotech stocks face some key make-or-break events in June that could have big implication for their futures.

Via InvestorPlace

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗

May 31, 2022

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...

Via Benzinga

3 Stocks to Buy the Dip Now ↗

May 20, 2022

You've heard the adage "buy the dip," but not all dips are made equal. There are several strategies for finding worthwhile discounted stocks.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Thursday ↗

May 05, 2022

During Thursday, 351 stocks hit new 52-week lows.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

Sections

Services

Contact Information

Follow Us